KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication.

John Davis, Daisy Zamora, Mark Horowitz, Stefan Leucht

Expert Opin Pharmacother 22(13) 1651-1660

PMID34404290
PMCID-
DOI10.1080/14656566.2021.1942455
发表日期2021-08-18
摘要

摘要

Introduction: Pimavanserin is FDA-approved to treat hallucinations and delusions associated with Parkinson's disease psychosis. As a potent 5-HT2A inverse agonist/antagonist, it could be efficacious in other psychiatric disorders. Recently, several studies have investigated this potential.Areas covered: The authors review the efficacy and adverse effects of pimavanserin for hallucinations in dementia, major depression, and schizophrenia.Expert opinion: Two controlled studies suggest pimavanserin has potential as a treatment for hallucinations in dementia. In patients with depression who did not respond to antidepressant treatment, pimavanserin augmentation was efficacious in a phase 2 study. Pimavanserin augmentation also alleviated sexual side effects of SSRI and SSNI. However, Acadia Pharmaceuticals stated in a press release that it does not plan further antidepressant trials based on its phase 3 trial, which showed a nonsignificant trend toward an antidepressant effect. Since almost all existing antipsychotics fail to substantially benefit negative symptoms, better treatments are needed. Pimavanserin augmentation of antipsychotics did benefit negative symptoms (effect size≈0.2) but failed to reduce the total PANSS score significantly in two large, well-controlled double-blind studies. Pimavanserin has a good safety profile.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。